hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06331052, orgStudyIdInfo id: 23-2431, secondaryIdInfos id: 1R01NS125386-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1R01NS125386-01, briefTitle: 3-D Tractography FUS Ablation for Essential Tremor, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2028-02-28, completionDateStruct date: 2028-02-28, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: University of North Carolina, Chapel Hill, class: OTHER, collaborators name: Texas Tech University Health Sciences Center, El Paso, collaborators name: University of Pittsburgh, collaborators name: National Institute of Neurological Disorders and Stroke (NINDS), descriptionModule briefSummary: The investigators propose to advance Vim-FUSA (Ventral Intermediate Nucleus - Focused Ultrasound Ablation) with the support of 3-D tractography, a neuroimaging technique to visually represent nerve tracts within the brain. The investigators hypothesize that 3-D tractography Vim-FUSA will improve the Vim ablation compared to standard Vim-FUSA and prove safe and feasible in the clinical setting. The investigators also hypothesize that intraoperative magnetic resonance (i-MR) monitoring will differentiate ablated tissue from immediate perilesional edema and accurately predict the Vim-FUSA clinical outcomes., conditionsModule conditions: Essential Tremor, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: MR-guided Focused Ultrasound Ablation, outcomesModule primaryOutcomes measure: Number of Participants without Side Effects, primaryOutcomes measure: Absolute Change in Tremor, primaryOutcomes measure: Relative Change in Tremor, secondaryOutcomes measure: Number of Participants with Procedure-Related Side Effects, secondaryOutcomes measure: Relative Change in Tremor-Related Quality of Life, secondaryOutcomes measure: Number of Participants Who Are Satisfied with Treatment, otherOutcomes measure: Change in Tremor Based on Video Assessment, otherOutcomes measure: Change in Gait Based on Video Assessment, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of North Carolina at Chapel Hill, status: RECRUITING, city: Chapel Hill, state: North Carolina, zip: 27999, country: United States, contacts name: Mary Ann Barnett, MLS, role: CONTACT, phone: 919-966-8804, email: mary-ann_barnett@med.unc.edu, contacts name: Vibhor Krishna, MD, SM, role: CONTACT, phone: 919-445-2410, email: vibhor_krishna@med.unc.edu, contacts name: Vibhor Krishna, MD, SM, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False
protocolSection identificationModule nctId: NCT06331039, orgStudyIdInfo id: CelalBayarU-5, briefTitle: The Effects of Pelvic Floor Muscle Training and Balance Exercises in Elderly People With Incontinence, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2024-04-05, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Celal Bayar University, class: OTHER, collaborators name: Dokuz Eylul University, collaborators name: Saglik Bilimleri Universitesi, descriptionModule briefSummary: Pelvic floor muscle weakness is one of the most important causes of incontinence. There are many studies supporting that pelvic floor muscle training prevents incontinence and reduces symptom severity, and with A level of evidence, it is among the first in the conservative treatment of incontinence. Functional status and balance problems are common in elderly people with incontinence, and it is known that functional type incontinence is common. Elderly people with incontinence most often fall while trying to get to the toilet. Balance exercises are recommended for falls and balance problems.The aim of this study is to examine the effects of pelvic floor muscle training and balance exercises on ankle muscle function, joint range of motion and balance in individuals aged 65 and over with urinary incontinence., conditionsModule conditions: Urinary Incontinence, conditions: Pelvic Floor Muscle Weakness, conditions: Muscle Weakness, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: PFMT, interventions name: PFMT+Balance, outcomesModule primaryOutcomes measure: ankle muscle function, primaryOutcomes measure: ankle range of motion, primaryOutcomes measure: muscle strength, primaryOutcomes measure: incontinence symptoms and severity, primaryOutcomes measure: incontinence symptoms and severity, primaryOutcomes measure: balance, primaryOutcomes measure: bladdery diary, primaryOutcomes measure: functional performance, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 100 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Melda BAŞER SEÇER, city: Mani̇sa, state: Yunusemre, zip: 45000, country: Turkey, contacts name: Melda BAŞER SEÇER, PhD, role: CONTACT, phone: +905547285453, email: melda.secer@cbu.edu.tr, contacts name: Özge ÇELİKER TOSUN, Assos. Prof., role: CONTACT, phone: +905055252029, email: ozge.tosun@deu.edu.tr, geoPoint lat: 38.61202, lon: 27.42647, hasResults: False
protocolSection identificationModule nctId: NCT06331026, orgStudyIdInfo id: GenSci004-106, briefTitle: A Bioequivalence Study of Two Different PEG-rhGH Preparations., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-07, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Changchun GeneScience Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to investigate whether PEG-rhGH with new preparation is bioequivalent to PEG-rhGH with present preparation., conditionsModule conditions: Pediatric Growth Hormone Deficiency (PGHD), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 87, type: ESTIMATED, armsInterventionsModule interventions name: PEG-rhGH with new preparation (T), interventions name: PEG-rhGH with present preparation (R), outcomesModule primaryOutcomes measure: Pharmacokinetics (Peak Plasma Concentration (Cmax) ) of PEG-rhGH with present and new preparation, primaryOutcomes measure: Pharmacokinetics (Area under the concentration-time curve from time zero to time infinity (AUC0-inf)) of PEG-rhGH with present and new preparation, primaryOutcomes measure: Pharmacokinetics (Area under the concentration-time curve from time zero to the time of the last quantifiable (AUC0- last )) of PEG-rhGH with present and new preparation, secondaryOutcomes measure: Safety and tolerability（Number of participants with treatment-related adverse events）, otherOutcomes measure: Anti-drug antibody (Number of Participants with positive ADA), eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Chengdu Xinhua Hospital, city: Chengdu, state: Sichuan, zip: 610000, country: China, contacts name: Xiaolan Yong, Doctor, role: CONTACT, phone: +86-28-60212136, email: yongxlan@126.com, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06331013, orgStudyIdInfo id: IEO 1872, briefTitle: CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr, acronym: PRO-SPEED, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-20, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: This is a prospective observational study. The study will proceed with the enrollment of 60 patients in 2 years. he aim of the present study is to evaluate effectiveness of ultra-hypofractionated (UH) CyberKnife Stereotactic Body Radiation Therapy treatment on the whole prostate gland plus Simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL(s) in intermediate-unfavourable to high-risk Prostate Cancer (PCa) patients., conditionsModule conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: CyberKnife ultra-hypofractionated SBRT, outcomesModule primaryOutcomes measure: Number of Participants with Acute GU and GI toxicities (RTOG), primaryOutcomes measure: Number of Participants with Late GU and GI toxicities (RTOG), primaryOutcomes measure: Evaluation of patient-reported toxicity, primaryOutcomes measure: Evaluation of patient-reported quality of life, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Barbara Alicja Jereczek, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06330987, orgStudyIdInfo id: 15110_MANNELLA, briefTitle: Fetal Autonomic Nervous sysTem Evaluation, acronym: FANTE, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-08-13, primaryCompletionDateStruct date: 2025-09-28, completionDateStruct date: 2025-12-28, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: University of Pisa, class: OTHER, collaborators name: Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy, descriptionModule briefSummary: The autonomic nervous system (ANS) is involved in cardiovascular, metabolic and cognitive processes, so its study in the fetus can provide relevant functional diagnostic and prognostic information. In particular, the study of the fetal ANS allows us to understand the degree of nervous maturation reached by the fetus and any developmental disorders that could have an impact on the cardiovascular characteristics of the fetus.The goal of this open-label, non-randomized, prospective observational study is to study the fetal ANS in pregnant women between 23 and 40 weeks of gestation.The objetives are:* To Evaluate Fetal Autonomic Nervous System (FANTE) through the analysis of maternal electrocardiogram (ECG) and others clinical parameters usually used in pregnancy monitoring.* To identify any variations in the fetal ECG in the event of developmental or pathological maternal and/or fetal pregnancy.Participants will be recruited during ultrasound visits, information sessions, and hospitalizations after signing informed consent., conditionsModule conditions: Pregnancy Related, conditions: Pregnancy Disease, conditions: Pregnancy Complications, conditions: Pre-Eclampsia, conditions: Gestational Diabetes, conditions: ECG Electrode Site Reaction, conditions: Fetal Growth Retardation, conditions: Fetal Complications, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 186, type: ESTIMATED, armsInterventionsModule interventions name: electrocardiograph, outcomesModule primaryOutcomes measure: Fetal Autonomic Nervous sysTem Evaluation (FANTE), secondaryOutcomes measure: Maternal Assesment, secondaryOutcomes measure: Obstetric Complications and mode of Delivery, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azienda Ospedaliera Universitaria Pisana, status: RECRUITING, city: Pisa, zip: 56126, country: Italy, contacts name: Paolo Mannella, MD. PhD., role: CONTACT, phone: 0039.050.993523, email: paolo.mannella@unipi.it, geoPoint lat: 43.70853, lon: 10.4036, hasResults: False
protocolSection identificationModule nctId: NCT06330974, orgStudyIdInfo id: FinnATOPY, briefTitle: Allergy, Asthma, and Atopic Eczema in Finland, acronym: FinnATOPY, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10, primaryCompletionDateStruct date: 2032-12, completionDateStruct date: 2034-12, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Tampere University, class: OTHER, collaborators name: Professor Lauri Lehtimäki, collaborators name: Professor Mika Mäkelä, collaborators name: Professor Sanna Toppila-Salmi, collaborators name: Professor Ilkka Junttila, descriptionModule briefSummary: The summary is available at --\> https://www.finnatopy.fi/summary, conditionsModule conditions: Asthma, conditions: Asthma in Children, conditions: Allergy, conditions: Rhinitis, Allergic, conditions: Atopic Dermatitis, conditions: Allergen Immunotherapy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 2000000, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Epidemiology of atopic diseases and allergic sensitization profiles in Finland, primaryOutcomes measure: Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland, primaryOutcomes measure: Evaluate and improve the current use of diagnostic tests for atopic diseases, primaryOutcomes measure: Use and effectiveness of allergen immunotherapy in real world setting, primaryOutcomes measure: Direct and indirect costs related to atopic diseases and comorbidities, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tampere University, city: Tampere, country: Finland, geoPoint lat: 61.49911, lon: 23.78712, hasResults: False
protocolSection identificationModule nctId: NCT06330948, orgStudyIdInfo id: NYCU112183AEF, briefTitle: Effects of SugarCut® Unripe Guava Fruit Extract on Blood Glucose Regulation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: National Yang Ming University, class: OTHER, descriptionModule briefSummary: Guava (Psidium guajava) belongs to the Myrtle family. It is a tropical and subtropical fruit native to the Americas. Ripe guava fruit is sweet and delicious. It is rich in vitamins A, C and trace elements such as phosphorus, calcium and magnesium. In traditional medicine, guava fruit can be eaten raw, and the roots can treat stomach problems, abdominal pain, dysentery, and diabetes; the leaves can treat diabetes, abdominal pain, rheumatism, antipyretic, stomachache, anthelmintic, cholera, vomiting, diarrhea, enteritis and other symptoms. Guava leaf extract contains polyphenols. Studies have shown that guava leaf has antioxidant, blood sugar regulating and anti-cancer effects. Not only guava leaves, research has found that guava fruits are rich in vitamins, fiber and antioxidants, which have anti-inflammatory and anti-cancer effects. Preliminary research has found that the extract of red guava young fruit has more active ingredients - saponins and total polyphenol content, and its antioxidant capacity is also higher than that of mature guava. In vitro studies have found that guava fruit extract can increase the expression of GLUT4 gene and promote the entry of blood sugar into cells. At the same time, guava fruit extract can inhibit the formation of final glycated proteins (AGEs). The purpose of this study is to explore the effect of guava fruit extract on blood sugar regulation in humans and to evaluate its potential to be developed as a blood sugar regulation supplement., conditionsModule conditions: PreDiabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: SugarCut® Unripe Guava Fruit Extract, interventions name: Placebo group, outcomesModule primaryOutcomes measure: GLUT4 gene expression, primaryOutcomes measure: Hematology Test, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: National Yang Ming Chiao Tung University, status: RECRUITING, city: Taipei, state: Beitou Dist., zip: 112, country: Taiwan, contacts name: Tze-Fang Wang, Ph.D., role: CONTACT, phone: +886-2-28267907, email: tzefang@nycu.edu.tw, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06330935, orgStudyIdInfo id: 192-2023, briefTitle: Evaluating the Effect of Tranexamic Acid on the Clinical Outcomes in Patients With Traumatic Brain Injury, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: Evaluate the effect of tranexamic acid on mortality in pediatric patients with traumatic brain injury. This could potentially lead to improved treatment protocols and better outcomes for this vulnerable population., conditionsModule conditions: Traumatic Brain Injury, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Tranexamic Acid (TXA), interventions name: Normal saline, outcomesModule primaryOutcomes measure: The early traumatic brain injury-related death in the hospital, primaryOutcomes measure: The difference between treatment group in the Intracranial haemorrhage growth, primaryOutcomes measure: The difference between the treatment groups in the incidence of mortality, secondaryOutcomes measure: Need for neurosurgical management, secondaryOutcomes measure: Days in the intensive care unit, secondaryOutcomes measure: Need for blood transfusion, secondaryOutcomes measure: Adverse events, secondaryOutcomes measure: Pediatric Quality of Life (PedsQL), secondaryOutcomes measure: Pediatric Glasgow Outcome Scale Extended (GOS-E) Peds), eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06330896, orgStudyIdInfo id: 346/2566(IRB3), briefTitle: Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing, acronym: genetics MM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2028-04-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Siriraj Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are:* genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and/or NGS testing* genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients.* disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and/or genetic mutations detected by NGS.* correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients.The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing., conditionsModule conditions: Plasma Cell Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 498, type: ESTIMATED, outcomesModule primaryOutcomes measure: genetic landscape of PCD, secondaryOutcomes measure: genetic correlation, secondaryOutcomes measure: genetic landscape of relapse MM patients, secondaryOutcomes measure: overall survival, secondaryOutcomes measure: progression free survival, secondaryOutcomes measure: factor of genetic landscape differentiation, secondaryOutcomes measure: gender, secondaryOutcomes measure: age, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False